MedTrace Logo

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

NCT04669171 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-01-30

No results posted yet for this study

Summary

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

Conditions

Interventions

BIOLOGICAL

EO2463

Multiple dose of EO2463

DRUG

lenalidomide

D1-21 of 4-weekly cycles

BIOLOGICAL

rituximab

Multiple doses of rituximab

Sponsors & Collaborators

  • Enterome

    lead INDUSTRY

Principal Investigators

  • Jan Fagerberg, MD · Enterome

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-05
Primary Completion
2029-05-30
Completion
2034-05-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04669171 on ClinicalTrials.gov